RT Journal Article
SR Electronic
T1 Association of British Clinical Diabetologists (ABCD) and Diabetes UK joint position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021)
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP 204
OP 210
DO 10.7861/clinmed.2021-0045
VO 21
IS 3
A1 Umesh Dashora
A1 Robert Gregory
A1 Peter Winocour
A1 Ketan Dhatariya
A1 Susannah Rowles
A1 Andrew Macklin
A1 Gerry Rayman
A1 Dinesh Nagi
A1 Katie Whitehead
A1 Hannah Beba
A1 Parijat De
A1 Dipesh C Patel
A1 on behalf of the ABCD executive committee and Diabetes UK
YR 2021
UL http://www.rcpjournals.org/content/21/3/204.abstract
AB Sodium glucose co-transporter 2 (SGLT2) inhibitors are now an established class of medications for the treatment of type 2 diabetes (T2D), no longer reserved for use by specialists in diabetes. They are being used increasingly for their cardiac and renal benefits by primary care, cardiology and renal teams for indications in parallel with diabetes care as part of holistic management. This guidance provides essential information on SGLT therapy, including the main advantages and the important risks of which healthcare professionals should be aware.